Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults

Summary

This is a phase 2, randomized, controlled, observer-blind study to evaluate the immunogenicity and safety of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) subunit vaccine (SCB-2020S), when administered as 2-dose vaccination series 21 days apart to adults ≥ 18 years of age.

Timeline

Start

2021-08

Primary completion

2022-04

Completion

2022-04

Drugs

Indications